Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Norfolk Southern Corporation (NSC) Price & Performance

AbCellera Biologics IncTrade
Norfolk Southern CorporationTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Norfolk Southern Corporation — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while Norfolk Southern Corporation trades at $335.84 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 25.1× AbCellera Biologics Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLNSC
Market Cap
$2.99B$75.15B
Sector
HealthTechnology
52-Week High
$9.76$350.66
52-Week Low
$2.78$272.35
Enterprise Value
$2.58B$90.70B
Dividend Yield
1.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

Norfolk Southern Corporation

Norfolk Southern (NSC) trades at $335.41, up 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $369.67. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.52 exceeding expectations, driven by record revenue and volume growth. A pending merger with Union Pacific and a recent dividend declaration highlight ongoing corporate activity.

The outlook is positive, supported by strong operational performance and favorable industry trends, though risks include integration challenges from the merger, premium valuation metrics, and potential economic headwinds affecting freight demand. Investor sentiment is mixed, with analysts predominantly holding a neutral to bullish stance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Norfolk Southern Corporation

Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.

Read more on NSC